traM Antibody

What is TRAM and why is it important in immunological research?

TRAM (TICAM2) is a critical signaling adaptor protein that plays multiple roles in TLR signaling pathways. Traditionally, TRAM was known to act as a bridge between TLR4 and TRIF, orchestrating inflammatory responses to pathogen challenges. Recent research has revealed that TRAM also plays an unexpected role in TLR7 signaling, contributing significantly to antiviral immunity .

Key functions of TRAM include:

• Bridging TLR4 with TRIF to mediate inflammatory responses

• Interacting with TRAF6 via a specific binding motif (with E183 being a critical residue)

• Contributing to TLR7-mediated production of RANTES (CCL5) and type I interferons

• Facilitating IRF3 phosphorylation and nuclear translocation

• Physically interacting with MyD88 upon TLR7 stimulation

Understanding TRAM's multifaceted roles makes TRAM antibodies essential tools for researchers investigating innate immune responses, particularly in the context of viral infections and inflammatory diseases.

What are the primary applications of TRAM antibodies in research?

TRAM antibodies serve multiple critical functions in immunological research:

• Western blot analysis for detecting TRAM protein expression in different cell types and tissues

• Immunoprecipitation studies to investigate protein-protein interactions involving TRAM

• Immunofluorescence microscopy to examine subcellular localization patterns

• Flow cytometry for intracellular detection of TRAM in various cell populations

• Co-immunoprecipitation to study TRAM's dynamic interactions with other signaling molecules like TRAF6 and MyD88

These applications enable researchers to elucidate TRAM's role in immune signaling cascades and its contribution to inflammatory and antiviral responses. The versatility of TRAM antibodies across multiple experimental platforms makes them valuable tools for comprehensive studies of innate immune signaling mechanisms.

How do researchers validate TRAM antibodies for experimental specificity?

Validation of TRAM antibodies for specificity typically involves multiple complementary approaches:

• Western blot analysis across multiple cell lines to confirm detection of a band at the expected molecular weight (approximately 31 kDa for TRAM/TICAM2)

• Testing in TRAM-deficient cells or tissues as negative controls

• Comparing staining patterns with multiple antibodies targeting different epitopes of TRAM

• Blocking peptide experiments to confirm specificity

• Recombinant protein expression systems to verify antibody recognition

For example, the R&D Systems TRAM/TICAM2 antibody (AF4348) was validated by Western blot in multiple cell lines (Raji human Burkitt's lymphoma, C2C12 mouse myoblast, and NRK rat normal kidney cell lines), confirming cross-reactivity across species and specificity for TRAM/TICAM2 . Additional validation through flow cytometry and immunofluorescence microscopy further confirmed the antibody's specificity across different applications.

What types of TRAM antibodies are available for different research applications?

Researchers have access to various types of TRAM antibodies suitable for different experimental needs:

*Based on general antibody availability patterns for similar targets

The choice of antibody depends on the specific application, species being studied, and experimental conditions. For instance, polyclonal antibodies often provide stronger signals due to recognition of multiple epitopes, while monoclonal antibodies offer greater consistency across experiments. For cross-species studies, antibodies with demonstrated reactivity across human, mouse, and rat TRAM (like AF4348) are particularly valuable .

How can TRAM antibodies be used to elucidate TLR7 signaling pathways?

TRAM antibodies have been instrumental in revealing a previously unappreciated role of TRAM in TLR7 signaling pathways. To investigate this novel signaling axis:

• Use TRAM antibodies in co-immunoprecipitation experiments to detect TLR7-induced interactions between TRAM and MyD88, as demonstrated in research showing that "TRAM physically interacts with MyD88 upon TLR7 stimulation, but not under basal conditions" .

• Employ phospho-specific antibodies to monitor IRF3 phosphorylation in wild-type versus TRAM-deficient cells following TLR7 stimulation, since "TLR7-mediated phosphorylation and nuclear translocation of IRF3 was impaired in TRAM −/− cells" .

• Combine TRAM antibodies with antibodies against other signaling components (MyD88, TRIF, IRF3) in confocal microscopy to track the formation and trafficking of signaling complexes.

• Use TRAM antibodies in chromatin immunoprecipitation (ChIP) assays to investigate transcriptional regulation of interferon and chemokine genes during TLR7 activation.

This methodological approach has revealed that TRAM participates in a novel signaling axis containing "MyD88, TRAM and IRF3 towards the activation of anti-viral immunity" , expanding our understanding of TLR7-mediated antiviral responses.

What techniques best detect TRAM-TRAF6 interactions, and how should researchers optimize them?

Research has identified a critical interaction between TRAM and TRAF6 that regulates inflammatory responses to TLR4 activation. Optimal techniques for studying this interaction include:

• Co-immunoprecipitation (Co-IP):

  • Lyse cells in a buffer containing 1% NP-40, 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, and protease inhibitors

  • Pre-clear lysates with protein G beads

  • Immunoprecipitate with anti-TRAM antibody overnight at 4°C

  • Analyze precipitates by Western blot using anti-TRAF6 antibodies

• Proximity Ligation Assay (PLA):

  • Fix and permeabilize cells

  • Incubate with primary antibodies against TRAM and TRAF6

  • Apply PLA probes and perform ligation and amplification

  • Visualize interaction spots by fluorescence microscopy

• Mutational analysis:

  • Express wild-type TRAM or TRAM E183A (which disrupts TRAF6 binding)

  • Compare immunoprecipitation results to confirm specificity of interaction

Research has shown that "TRAM and TRAF6 association was confirmed by immunoprecipitation of endogenous, ectopically expressed and recombinant proteins, which was ablated upon mutation of a key Glu residue in TRAM (TRAM E183A)" . This mutation provides an excellent negative control to validate the specificity of detected interactions.

How do cell type and experimental conditions affect TRAM antibody detection?

Experimental conditions significantly impact TRAM antibody detection across different cell types:

• Cell type-specific expression levels:

  • Immune cells like macrophages and B cells (e.g., Raji cells) typically express higher levels of TRAM

  • Non-immune cells may require more sensitive detection methods

• Fixation and permeabilization conditions:

  • For flow cytometry: "To facilitate intracellular staining, cells were fixed with paraformaldehyde and permeabilized with saponin"

  • For adherent vs. non-adherent cells: Different protocols are required as noted in R&D Systems' documentation

• Antibody concentration optimization:

  • Different cell types may require different antibody dilutions

  • For Western blot: "Western blot analysis of extracts of various cell lines, using TRAM/TICAM2 antibody (NBP3-05623) at 1:1000 dilution"

The data demonstrates successful detection of TRAM/TICAM2 in multiple cell types using the same antibody but with cell-type specific protocol adjustments .

What are the methodological challenges in studying TRAM dynamics during viral infections?

TRAM antibodies provide valuable insights into viral infection mechanisms, but come with specific methodological challenges:

• Temporal dynamics of TRAM signaling:

  • Viral infection triggers rapid but transient signaling events

  • Time-course experiments are essential to capture optimal interaction windows

  • Synchronized infection protocols improve reproducibility

• Subcellular trafficking complications:

  • TRAM relocalization during infection requires careful fixation protocols

  • Live-cell imaging with fluorescently tagged antibody fragments may be needed for real-time dynamics

• Virus-specific considerations:

  • RNA viruses activate TLR7 pathways where "suppression of endogenous human TRAM expression in human macrophages significantly impaired RV16 induced CCL5 and IFNβ, but not TNFα gene induction"

  • Different viruses may trigger different TRAM-dependent pathways

• Technical approaches for capturing TRAM's role:

  • siRNA/shRNA knockdown combined with TRAM antibody detection

  • CRISPR-Cas9 knockout cells as negative controls

  • Reconstitution experiments with wild-type vs. mutant TRAM

• Data interpretation complexities:

  • TRAM contributes differentially to cytokine production (affects CCL5/IFNβ but not TNFα)

  • Pathway redundancy may mask TRAM contribution in some experimental systems

TRAM's involvement in antiviral immunity makes these methodological considerations particularly important for researchers studying viral pathogenesis and host defense mechanisms.

How can researchers distinguish between the different functional pools of TRAM in cells?

TRAM exists in different functional pools within cells, and distinguishing between them requires specialized approaches:

• Membrane-associated vs. cytosolic TRAM:

  • Subcellular fractionation followed by Western blot analysis

  • Use gentle detergents (0.1% digitonin) to preserve membrane associations

  • Confocal microscopy with dual staining for TRAM and membrane markers

• TLR4-associated vs. TLR7-associated TRAM:

  • Sequential immunoprecipitation with antibodies against different TLRs

  • Proximity ligation assays to visualize specific TRAM-TLR interactions in situ

  • Stimulation with pathway-specific ligands (LPS for TLR4, R848 for TLR7)

• Activated vs. inactive TRAM:

  • Phospho-specific antibodies (if available)

  • Differential extraction protocols to separate signaling complexes

  • Time-course analysis following stimulation

• Experimental strategies:

  • TRAM-deficient cells reconstituted with tagged TRAM variants

  • Domain-specific antibodies targeting functional regions of TRAM

  • Correlative light and electron microscopy for nanoscale localization

Research has demonstrated that TRAM serves distinct functions in different signaling pathways: "TRAM acts to bridge TLR4 with TRIF, orchestrating the inflammatory response to pathogen challenge" while also participating in "TLR7 signaling through a novel signaling axis containing, but not limited to, MyD88, TRAM and IRF3" .

What are the optimal protocols for TRAM antibody use in Western blot analysis?

Optimal Western blot protocols for TRAM antibodies:

• Sample preparation:

  • Lyse cells in RIPA buffer with protease inhibitors

  • Load 25μg protein per lane: "Lysates/proteins: 25ug per lane"

  • Include positive controls (cells known to express TRAM) and negative controls when possible

• Gel electrophoresis and transfer:

  • Use 10-12% SDS-PAGE gels for optimal resolution around 31 kDa (TRAM's molecular weight)

  • Transfer to PVDF membrane: "PVDF membrane was probed with 1 μg/mL of Human/Mouse/Rat TRAM/TICAM2 Antigen Affinity-purified Polyclonal Antibody"

• Blocking and antibody incubation:

  • Block with 3% nonfat dry milk in TBST: "Blocking buffer: 3% nonfat dry milk in TBST"

  • Dilute primary antibody appropriately: "1:500-1:2000"

  • Incubate with appropriate secondary antibody: "HRP Goat Anti-Rabbit IgG (H+L) at 1:10000 dilution"

• Detection and analysis:

  • Use ECL detection: "Detection: ECL Basic Kit. Exposure time: 30s"

  • Expected band size: "A specific band was detected for TRAM/TICAM2 at approximately 31 kDa"

  • For quantification, normalize to appropriate loading controls

These parameters should be optimized for each experimental system to achieve the best signal-to-noise ratio while ensuring specificity of detection.

How can co-immunoprecipitation with TRAM antibodies be optimized for interaction studies?

To optimize co-immunoprecipitation for detecting TRAM interactions:

• Cross-linking approach for transient interactions:

  • Treat cells with membrane-permeable cross-linkers (e.g., DSP) to stabilize transient interactions

  • Quench and lyse cells under denaturing conditions

  • Dilute lysates before immunoprecipitation

• Stimulation timing optimization:

  • Perform careful time-course experiments to capture the optimal window for interaction

  • For TLR7-MyD88-TRAM interactions, examine early time points after stimulation

  • For TRAM-TRAF6, consider both basal and stimulated conditions

• Buffer optimization:

  • Use buffers with lower ionic strength to preserve weaker interactions

  • Include phosphatase inhibitors to maintain phosphorylation-dependent interactions

  • Consider digitonin-based lysis buffers to preserve membrane-associated complexes

• Antibody orientation strategies:

  • Perform reciprocal IPs (anti-TRAM followed by Western blot for partner, and vice versa)

  • Use antibodies targeting different epitopes to ensure accessibility

  • Consider pre-clearing lysates with protein A/G beads to reduce non-specific binding

• Critical controls:

  • Include isotype control antibodies

  • Use TRAM-deficient cells as negative controls

  • For TRAM-TRAF6 interaction, include the TRAM E183A mutant as specificity control

Research has demonstrated successful co-immunoprecipitation of TRAM with its interaction partners: "TRAM physically interacts with MyD88 upon TLR7 stimulation, but not under basal conditions" .

What are the recommended protocols for TRAM antibody use in flow cytometry?

Key considerations for flow cytometry with TRAM antibodies:

• Cell preparation and fixation:

  • Harvest cells gently to maintain integrity

  • Fix with paraformaldehyde: "To facilitate intracellular staining, cells were fixed with paraformaldehyde and permeabilized with saponin"

  • Optimize fixation time (typically 10-15 minutes) to preserve epitopes

• Permeabilization optimization:

  • For TRAM detection, saponin permeabilization is effective

  • Maintain saponin in all wash and staining buffers

  • Alternative: 0.1% Triton X-100 for stronger permeabilization

• Antibody incubation:

  • Use appropriate primary antibody concentration

  • Include matched isotype controls: "isotype control antibody (Catalog # AB-108-C, open histogram)"

  • Select appropriate secondary antibodies: "Phycoerythrin-conjugated Anti-Goat IgG Secondary Antibody (Catalog # F0107)"

• Data acquisition and analysis:

  • Set proper compensation when using multiple fluorophores

  • Analyze shifts in fluorescence intensity compared to isotype controls

  • Consider intracellular staining controls (known positive and negative cell types)

These protocols provide a starting point that should be optimized for specific experimental systems.

How should researchers approach immunofluorescence microscopy with TRAM antibodies?

Effective immunofluorescence microscopy protocols for TRAM antibodies:

• Sample preparation considerations:

  • For adherent cells: culture on coated coverslips

  • For suspension cells: "View our protocol for Fluorescent ICC Staining of Non-adherent Cells"

  • Consider poly-L-lysine coating for improved cell attachment

• Fixation and permeabilization:

  • Standard protocol: 4% paraformaldehyde fixation (10-15 minutes)

  • Permeabilization: "Cells were stained using the NorthernLightsTM 557-conjugated Anti-Goat IgG Secondary Antibody (red, upper panel; Catalog # NL001) and counterstained with DAPI (blue, lower panel)"

  • Optimize permeabilization time for consistent results

• Antibody incubation parameters:

  • Use optimized antibody concentration: "TRAM/TICAM2 was detected... using Human/Mouse/Rat TRAM/TICAM2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF4348) at 10 μg/mL for 3 hours at room temperature"

  • Include appropriate blocking steps to reduce non-specific binding

  • Incubate with fluorescently-labeled secondary antibodies

• Image acquisition and analysis:

  • Use appropriate filter sets for selected fluorophores

  • Acquire z-stack images for three-dimensional analysis

  • Apply consistent exposure settings across experimental conditions

• Expected subcellular localization:

  • "Specific staining was localized to cytoplasm" for TRAM/TICAM2

  • Consider co-staining with organelle markers to define precise localization

  • Analyze redistribution following cellular stimulation

High-quality microscopy images require careful optimization of these parameters to balance signal intensity with background reduction.

How to address non-specific binding issues when using TRAM antibodies?

Non-specific binding can be addressed through several strategies:

• Antibody validation approaches:

  • Confirm antibody specificity using TRAM-deficient cells or tissues

  • Test multiple antibodies targeting different epitopes

  • Use peptide competition assays to confirm specificity

  • Include appropriate isotype controls

• Blocking optimization:

  • For Western blot: "Blocking buffer: 3% nonfat dry milk in TBST"

  • For immunofluorescence: Consider 5% BSA or serum from the same species as the secondary antibody

  • Extend blocking time for high-background samples (1-2 hours at room temperature)

• Antibody dilution optimization:

  • Titrate antibodies to find optimal concentration: "1:500-1:2000" for Western blot

  • Higher dilutions may reduce background but require longer incubation times

  • For IF/flow cytometry: test a range of concentrations around manufacturer recommendations

• Washing protocol enhancement:

  • Increase number and duration of wash steps

  • Add detergent (0.05-0.1% Tween-20) to wash buffers

  • For immunofluorescence, consider using PBS with higher salt concentration

• Secondary antibody considerations:

  • Use highly cross-adsorbed secondary antibodies

  • Consider directly conjugated primary antibodies to eliminate secondary antibody issues

  • Match secondary antibody to host species of primary antibody

These approaches should be systematically tested to identify the optimal conditions for specific detection of TRAM while minimizing background signals.

What strategies effectively overcome low signal issues with TRAM antibodies?

To overcome low signal issues when working with TRAM antibodies:

• Sample enrichment techniques:

  • Increase protein loading: "Lysates/proteins: 25ug per lane"

  • For immunoprecipitation before Western blot: Use larger starting sample volume

  • Consider subcellular fractionation to concentrate TRAM from relevant compartments

• Signal amplification methods:

  • For Western blot: Use more sensitive ECL substrates

  • For immunofluorescence: Try tyramide signal amplification (TSA)

  • For flow cytometry: Consider using brighter fluorophores or amplification systems

• Detection system optimization:

  • Extend primary antibody incubation time (overnight at 4°C)

  • Optimize secondary antibody concentration and incubation time

  • For immunofluorescence: Use longer exposure times or more sensitive cameras

• Epitope retrieval considerations:

  • For fixed tissues: Test antigen retrieval methods (heat-induced or enzymatic)

  • For Western blot: Ensure complete protein denaturation

  • Consider milder fixation protocols to preserve epitope structure

• Antibody selection strategies:

  • Compare polyclonal vs. monoclonal antibodies (polyclonals often provide stronger signals)

  • Test antibodies targeting different epitopes of TRAM

  • Consider antibodies validated specifically for your application of interest

Implementing these strategies should help maximize signal while maintaining specificity for reliable detection of TRAM proteins across different experimental platforms.

How can researchers differentiate between closely related TLR adaptor proteins?

Distinguishing TRAM from other TLR adaptors requires specific methodological approaches:

• Antibody selection and validation:

  • Use antibodies raised against unique regions of TRAM not conserved in other adaptors

  • Validate specificity using knockdown/knockout controls for each adaptor

  • Test for cross-reactivity with recombinant proteins of each adaptor

• Western blot differentiation:

  • TRAM/TICAM2: ~31 kDa

  • MyD88: ~33 kDa

  • TRIF/TICAM1: ~80 kDa

  • TIRAP/Mal: ~25 kDa

  • Use high-resolution gels (10-12%) to separate closely sized proteins

• Functional validation approaches:

  • Complement reconstitution experiments in adaptor-deficient cells

  • Use pathway-specific stimuli (e.g., TLR4 vs. TLR7 agonists)

  • Analyze adaptor-specific downstream responses (e.g., "TRAM-deficient macrophages reconstituted with TRAM E183A display significantly reduced inflammatory TNF-α, IL-6, and RANTES protein production compared with WT TRAM" )

• Co-localization studies:

  • Perform double-immunofluorescence with antibodies against different adaptors

  • Use super-resolution microscopy to resolve closely associated proteins

  • Analyze redistribution patterns following specific stimuli

• Genetic tools:

  • CRISPR-Cas9 knockout of specific adaptors

  • siRNA knockdown with validated siRNAs targeting unique regions

  • Rescue experiments with tagged adaptor proteins

These approaches enable researchers to specifically identify and study TRAM's unique functions distinct from other TLR adaptor proteins.

How might emerging antibody technologies advance TRAM research?

Emerging antibody technologies offer new possibilities for TRAM research:

• Single-domain antibodies (nanobodies):

  • Smaller size enables access to cryptic epitopes

  • Potential for intracellular expression to track TRAM in living cells

  • Greater stability under various experimental conditions

• Proximity-based labeling:

  • TRAM antibody fusions with enzymes like BioID or APEX2

  • Allows identification of transient interaction partners

  • Maps the dynamic TRAM interactome under different stimulation conditions

• Site-specific antibodies:

  • Development of antibodies specific to post-translationally modified TRAM

  • Enables monitoring of activation states and signaling dynamics

  • Helps distinguish functionally distinct pools of TRAM

• Single-cell analysis tools:

  • Mass cytometry (CyTOF) with TRAM antibodies

  • Spatial transcriptomics combined with TRAM protein detection

  • Single-cell western blotting for heterogeneity analysis

• In vivo applications:

  • Near-infrared labeled TRAM antibodies for in vivo imaging

  • Antibody-drug conjugates for targeted manipulation of TRAM-expressing cells

  • Intrabodies for real-time tracking of TRAM signaling dynamics

These technologies hold promise for advancing our understanding of TRAM's roles in health and disease beyond what conventional antibody applications have revealed.

What are the implications of TRAM research for therapeutic antibody development?

TRAM research has significant implications for therapeutic antibody development:

• Targeting TLR signaling pathways:

  • TRAM's role in both TLR4 and TLR7 signaling makes it a potential target for modulating multiple pathways

  • Structural insights from TRAM research inform design of antibodies that disrupt specific interactions

  • The discovery that "TRAM plays a, hitherto unappreciated, role in TLR7 signaling" opens new therapeutic avenues

• Therapeutic antibody engineering insights:

  • "Discovery and optimization platforms to generate highly specific V regions with a higher human content for therapeutic settings combined with Fc engineering have enabled the approval of 21 antibodies to treat cancer"

  • Understanding TRAM signaling provides biological context for these engineering efforts

• Applications in inflammatory and autoimmune diseases:

  • Targeting TRAM-dependent signaling may provide more selective immunomodulation than general TLR inhibition

  • The finding that "TRAM interaction with TRAF6 regulates the inflammatory response to TLR4 activation" suggests potential for targeting this specific interaction

• Viral infection interventions:

  • TRAM's role in responses to "ssRNA viruses such as human rhinovirus (HRV) and Influenza, against which there are currently no treatments or vaccines with long term efficacy available" highlights potential therapeutic applications

  • Antibodies modulating TRAM function could enhance antiviral immunity

• Antibody development considerations:

  • Species cross-reactivity (human/mouse/rat) facilitates translational research

  • Epitope selection critical for targeting specific TRAM functions

  • Format considerations (whole antibodies vs. fragments) based on application

The continuous advancement in understanding TRAM biology through antibody-based research provides valuable insights for developing next-generation therapeutics targeting innate immune signaling pathways.